贝伐珠单抗联合信迪利单抗治疗对原发性肝癌患者肝癌标志物及细胞凋亡因子水平的影响  

Effect of bevacizumab combined with sintilimab on hepatoma markers and apoptosis factors of patients with primary liver cancer

作　　者：胡震霆[1] HU Zhenting(Department of Infectious Diseases,Affiliated Hospital of Putian University,Putian 351100,Fujian,China)

机构地区：[1]莆田学院附属医院感染性疾病科,福建莆田351100

出　　处：《延边大学医学学报》2024年第2期130-133,共4页Journal of Medical Science Yanbian University

基　　金：福建省中青年教师教育科研项目,编号:JAT210178.

摘　　要：[目的]探讨贝伐珠单抗联合信迪利单抗治疗对原发性肝癌患者肝癌标志物及细胞凋亡因子的影响.[方法]选择2022年1月—2024年1月间莆田学院附属医院感染性疾病科收治的80例原发性肝癌患者,采用随机数表法分为对照组和观察组,每组各40例,对照组给予信迪利单抗治疗,观察组给予贝伐珠单抗联合信迪利单抗治疗.比较两组原发性肝癌治疗的总有效率、不良反应发生率、治疗前后的肝癌标志物(G73、AFP-L3及AFP)及细胞凋亡因子(sFas、sFasL及Caspase-3)水平.[结果]观察组原发性肝癌治疗的总有效率显著高于对照组(P<0.05),两组不良反应发生率间差异无统计学意义(P>0.05),治疗前两组的肝癌标志物及细胞凋亡因子水平间差异均无统计学意义(P>0.05),治疗4个疗程后观察组的肝癌标志物及sFas、sFasL水平显著低于对照组(P<0.05),Caspase-3水平显著高于对照组(P<0.05).[结论]贝伐珠单抗联合信迪利单抗在治疗原发性肝癌患者中的临床效果较好,可显著改善肝癌标志物及细胞凋亡因子水平,在原发性肝癌治疗中的应用价值较高.OBJECTIVE To investigate the influence of bevacizumab combined with sintilimab on hepatoma markers and apoptosis factors of patients with primary liver cancer.METHODS A total of 80 patients with primary liver cancer admitted to the Department of Infectious Diseases of the Affiliated Hospital of Putian University from January 2022 to January 2024 were selected and divided into the control group and the observation group by the random number table method,with 40 cases in each group.The control group was treated with sintilimab,and the observation group was treated with bevacizumab combined with sintilimab.The total effective rate of primary liver cancer treatment,the incidence of adverse reactions,the levels of hepatoma markers(G73,AFP-L3 and AFP)and apoptosis factors(sFas,sFasL and Caspase-3)before and after the treatment of two groups were compared.RESULTS The total effective rate of primary liver cancer treatment of the observation group was significantly higher than that of the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).There was no significant difference in the levels of the hepatoma markers and apoptosis factors between the two groups before the treatment(P>0.05).The hepatoma markers,sFas and sFasL levels of the observation group after the treatment of four courses were significantly lower than those of the control group(P<0.05),and the level of Caspase-3 was significantly higher than that of the control group(P<0.05).CONCLUSION Bevacizumab combined with sintilimab has a good clinical effect in the treatment of patients with primary liver cancer,which can significantly improve the levels of hepatoma markers and apoptosis factors,and has a high application value in the treatment of primary liver cancer.

关 键 词：原发性肝癌 贝伐珠单抗 信迪利单抗 肝癌标志物 细胞凋亡因子 

分 类 号：R735.7[医药卫生—肿瘤]